NCT06519526View on ClinicalTrials.gov

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

August 31, 2027

Conditions
Relapsed/Refractory Peripheral T Cell Lymphoma
Interventions
DRUG

SHR-0302

SHR-0302 will be administered orally as tablets.

DRUG

SHR-2554

SHR-2554 will be administered orally as tablets.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER